Year: All Releases2018201720162015201420132012 December 20, 2017 Mersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference PDF Version December 15, 2017 Mersana Therapeutics Added to NASDAQ Biotechnology Index PDF Version December 12, 2017 Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors PDF Version 169.9 KB November 9, 2017 Mersana Announces Third Quarter 2017 Financial Results and Provides Business Updates PDF Version 357 KB October 30, 2017 Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b PDF Version 540.7 KB October 30, 2017 Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference PDF Version 545.6 KB October 23, 2017 Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PDF Version September 5, 2017 Mersana Appoints Lawrence M. Alleva to Board of Directors PDF Version August 31, 2017 Mersana Therapeutics to Participate in Investor Conferences in September PDF Version August 11, 2017 Mersana Announces Second Quarter 2017 Financial Results and Provides Business Updates PDF Version Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last
